Bayer Aktiengesellschaft (BAYRY)
| Market Cap | 44.82B +72.8% |
| Revenue (ttm) | 52.16B -2.9% |
| Net Income | -2.49B |
| EPS | -2.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.77 |
| Dividend | 0.02 (0.21%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 5,425,466 |
| Average Volume | 1,663,783 |
| Open | 11.21 |
| Previous Close | 11.05 |
| Day's Range | 11.20 - 11.42 |
| 52-Week Range | 6.55 - 14.85 |
| Beta | 0.84 |
| RSI | 53.51 |
| Earnings Date | May 12, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical product... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Bayer (BAYRY) to Buy from Hold with a EUR 51 price target
Bayer granted priority review for asundexian by FDA
Bayer (BAYRY) announced that the FDA has accepted the company’s new drug application and granted priority review designation for its investigational oral Factor XIa inhibitor, asundexian, for the prev...
Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention
(RTTNews) - Bayer AG (BAYRY) announced that the U.S. FDA has accepted its NDA and granted Priority Review for Asundexian, an investigational oral Factor Xla (FXla) inhibitor, for the prevention of sec...
Bayer (BAYRY) Receives FDA Priority Review for Asundexian in Stroke Prevention
Bayer (BAYRY) Receives FDA Priority Review for Asundexian in Stroke Prevention
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT'S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) and granted Priori...
EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Bayer (BAYRY) Settles Toxic Contamination Claims for $133M
Bayer (BAYRY) Settles Toxic Contamination Claims for $133M
Bayer agrees to pay $133 million for PCB cleanup in two states
Bayer's Monsanto unit on Monday said it would pay at least $133 million to settle Michigan and Rhode Island's claims that the company contaminated the states' natural resources with toxic chemicals ...
Bayer Gets FDA Priority Review For Hyrnuo In First-Line HER2-Mutated Lung Cancer
LEVERKUSEN (dpa-AFX) - Bayer AG (BYR.L) on Monday said the U.S. Food and Drug Administration has granted priority review for Hyrnuo as a first-line treatment for HER2-mutated non-small cell lung c...
Bayer announces HYRNUO sNDA granted Priority Review status by FDA
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has granted HYRNUO Priority Review status for the first-line treatment of adult patients with locally advanced or metastatic non-smal...
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted HYRNUO (sevabertinib) Priority Review status for the first-line treatment of adult patients with locally advanced or ...
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
WHIPPANY, N.J.--(BUSINESS WIRE)--Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a camp...
Bayer Introduces Midol in Motion, Empowering Menstruators to Find PMS Relief Through Movement
Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol in Motion, a campaign focused on helping people bet...
Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum
Bayer Aktiengesellschaft ETR: BAYN executives said the company's Crop Science division remains on track with a five-year plan centered on cost savings, margin expansion and a slate of product launches...
Bayer Aktiengesellschaft Transcript: 21st Annual Global Farm to Market Conference
A five-year strategy is on track, emphasizing margin expansion, cost savings, and a robust innovation pipeline with major product launches planned through 2029. Market dynamics remain stable in North America and Brazil, while global uncertainties and supply chain pressures persist. Legal progress on glyphosate litigation and new biofuel partnerships further shape the outlook.
Bayer Aktiengesellschaft Transcript: 21st Annual Global Farm to Market Conference
A five-year strategy is on track, emphasizing margin expansion, cost savings, and a robust innovation pipeline with major product launches planned through 2029. Market dynamics remain stable in North America and Brazil, while global uncertainties and supply chain pressures persist. Legal progress on glyphosate litigation and new biofuel partnerships further shape the outlook.
Bayer launches 2026 campaign to expand food access with Luke Bryan
Bayer (BAYRY) and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America, with Bayer…
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America...
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America to Expand Access to Food and Nutrition in Rural Communities
Bayer and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America, with Bayer donating 1 million m...
Bayer AG (BAYRY) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Cash Flow Challenges
Bayer AG (BAYRY) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Cash Flow Challenges
European Markets Decline Amid Iran Tensions; Bayer (BAYRY) Surges on Strong Earnings
European Markets Decline Amid Iran Tensions; Bayer (BAYRY) Surges on Strong Earnings
Bayer Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% sales growth and higher EPS, driven by Crop Science and Consumer Health, while Pharma remained flat. Litigation settlements and regulatory clarity efforts progressed, and the full-year outlook was confirmed despite FX and geopolitical risks.
Bayer Aktiengesellschaft Quarterly report: Q1 2026
Bayer Aktiengesellschaft has published its Q1 2026 quarterly earnings report on May 12, 2026.
Bayer Aktiengesellschaft Earnings release: Q1 2026
Bayer Aktiengesellschaft released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Bayer Aktiengesellschaft Slides: Q1 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.